AVTX Stock Summary and Trading Ideas (Avalo Therapeutics | NASDAQ:AVTX)

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Avalo Therapeutics trades on the NASDAQ stock market under the symbol AVTX.

As of May 26, 2026, AVTX stock price declined to $16.02 with 1,294,811 million shares trading.

AVTX has a beta of 1.48, meaning it tends to be more sensitive to market movements. AVTX has a correlation of 0.04 to the broad based SPY ETF.

AVTX has a market cap of $842.10 million. This is considered a Small Cap stock.

In the last 3 years, AVTX traded as high as $1,130.31 and as low as $3.39.

The top ETF exchange traded funds that AVTX belongs to (by Net Assets): VTI, VXF, IWC, ITOT, TMSL.

AVTX has outperformed the market in the last year with a return of +309.7%, while the SPY ETF gained +30.0%. In the last 3 month period, AVTX beat the market returning +12.7%, while SPY returned +9.1%. However, in the most recent 2 weeks AVTX has underperformed the stock market by returning -25.7%, while SPY returned +1.8%.

AVTX support price is $15.23 and resistance is $17.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVTX shares will trade within this expected range on the day.